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Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the developed
countries and is caused by both environmental and genetic factors. A recent study (Tuo et al., PNAS) reported an association
between AMD and a single nucleotide polymorphism (SNP) (rs3793784) in the ERCC6 (NM_000124) gene. The risk allele also
increased ERCC6 expression. ERCC6 is involved in DNA repair and mutations in ERCC6 cause Cockayne syndrome (CS).
Amongst others, photosensitivity and pigmentary retinopathy are hallmarks of CS.
Methodology/Principal Findings: Separate and combined data from three large AMD case-control studies and a
prospective population-based study (The Rotterdam Study) were used to analyse the genetic association between ERCC6
and AMD (2682 AMD cases and 3152 controls). We also measured ERCC6 mRNA levels in retinal pigment epithelium (RPE)
cells of healthy and early AMD affected human donor eyes. Rs3793784 conferred a small increase in risk for late AMD in the
Dutch population (The Rotterdam and AMRO-NL study), but this was not replicated in two non-European studies (AREDS,
Columbia University). In addition, the AMRO-NL study revealed no significant association for 9 other variants spanning
ERCC6. Finally, we determined that ERCC6 expression in the human RPE did not depend on rs3793784 genotype, but,
interestingly, on AMD status: Early AMD-affected donor eyes had a 50% lower ERCC6 expression than healthy donor eyes
(P=0.018).
Conclusions/Significance: Our meta-analysis of four Caucasian cohorts does not replicate the reported association between
SNPs in ERCC6 and AMD. Nevertheless, our findings on ERCC6 expression in the RPE suggest that ERCC6 may be functionally
involved in AMD. Combining our data with those of the literature, we hypothesize that the AMD-related reduced
transcriptional activity of ERCC6 may be caused by diverse, small and heterogeneous genetic and/or environmental
determinants.
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Introduction
Age-related macular degeneration (AMD) is the most common
cause of irreversible blindness in the Western world. The
prevalence of AMD rises sharply with age, affecting 4% of the
population over the age of 60 and more than 10% of individuals
older than 75 [1,2]. The early stages of AMD are characterized by
drusen, which are focal depositions of waste material underneath
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frequently progress over time into late AMD, which presents itself
in two forms: geographic atrophy (dry AMD) and neovascular
AMD (wet AMD).
As a complex disease, AMD has environmental as well as
genetic determinants.
Environmental risk factors include age, smoking, hypertension
and diet. Estimates of the genetic hereditability range up to 71%
[3,4]. The strongest genetic associations with AMD were found
with variants in the complement factor H (CFH) gene [5–8] and
with SNPs in a chromosomal region (10q26) containing the
HTRA1 and ARMS2 genes [9,10]. CFH is the main inhibitor of the
alternative pathway of the complement system, and thus plays an
important role in the control of the innate immune system.
Recently, associations with AMD were also found for other genes
of the complement cascade (complement factor B, C2, C3 [11–13],
but, interestingly enough, not for C5, although it should be noted
that only relatively common SNP’s in C5 were screened [14].
Nonetheless, the accumulated evidence in the literature suggests a
key role of the alternative complement pathway in AMD. Whether
genetic variants in the HTRA1 or ARMS2 genes on 10q26, or both,
are truly involved in AMD remains to be elucidated [15,16]. In
terms of function, both genes could play a role in AMD: HTRA1 is
a serine protease [9] which may affect the turnover of the ECM
(i.e. Bruch’s membrane), while ARMS2 has been implicated in
mitochondrial function and oxidative stress [17].
Indeed, the retina, and especially the RPE is exposed to high
levels of oxidative stress [18]. The combination of high oxygen
consumption, intense light exposure and the presence of
photosensitizers such as lipofuscin, may lead locally to excessive
oxidative damage, for example of the DNA. In this respect, the
recent ERCC6/AMD manuscript of Tuo and coworkers (2006) is
of interest. They reported that a single nucleotide polymorphism
(SNP; rs3793784), in the promoter region of the ERCC6 DNA
repair gene was associated with AMD. The SNP was associated
with AMD susceptibility, both independently and through
interaction with a SNP (rs380390) in CFH.
In addition, they found that the ERCC6 SNP altered the
expression level of the gene [19].
The ERCC6 gene is involved in DNA repair, and loss of
function mutations in this gene cause Cockayne syndrome (CS)
[20,21]. CS is an autosomal recessive progeroid disorder
characterized by severely impaired physical and intellectual
development. Among the many clinical features, photosensitivity
and pigmentary retinopathy are hallmarks of CS [21]. Cells from
CS patients are specifically defective in repair of DNA lesions that
are located in actively transcribed DNA and obstruct transcription
[22,23]. Substrates for this transcription-coupled repair include
UV or oxidative stress induced DNA lesions [24–26]. DNA repair
deficiency of UV-induced DNA lesions may explain photosensi-
tivity in CS. DNA repair deficiency of oxidative stress induced
DNA lesions may be implicated in other CS symptoms, including
the retinopathy, and premature aging [27,28]. Targeted disruption
of Ercc6 in the mouse resulted in a mouse model for CS [29,30],
which showed spontaneous retinal degeneration characterized by
a gradual photoreceptor loss [29]. Interestingly, the retina of the
Ercc6 -/- mouse is hypersensitive to X rays, which confirmed that
oxidative DNA damage is involved in CS retinal pathology.
In order to further explore the role of oxidative DNA damage in
AMD, the potential association of ERCC6 promoter SNP
rs3793784: C.G (c.-6530C.G) with AMD was analyzed in the
population-based Rotterdam study and, in parallel, in the Dutch
AMRO-NL case-control study. Replication was performed in two
large non-European AMD case-control (Columbia University and
Age-Related Eye Disease Study (AREDS)) studies. We subse-
quently investigated the potential modifying effect of CFH Y402H,
LOC387715 A69S and smoking. Next, nine other ERCC6 (tag)
SNPs were genotyped in 375 cases and 199 controls from the
AMRO-NL study population. Finally, to examine a possible
functional relationship, we determined both rs3793784 dependent
and normal ERCC6 mRNA expression levels in healthy and early
AMD affected human RPE isolated from human donor eyes.
Results
Analysis of association for ERCC6 promoter
polymorphism rs3793784
The potential association of ERCC6 c.-6530C.G (rs3793784)
with AMD was analyzed in the population-based Rotterdam
Study and, in parallel, in the Dutch AMRO-NL case-control
study. In the Rotterdam Study, 427 of 6418 persons were
diagnosed with early AMD and 78 persons with late AMD at entry
of the study. The mean follow-up time was 7.85 years. In this
period, 1039 persons remained without AMD (‘‘controls’’), while
509 progressed to early AMD and 93 to late AMD (%). In the
AMRO-NL study, 331 unrelated AMD patients and 170 controls
were genotyped for rs3793784. Of those, 84 persons were
diagnosed with early AMD and 247 persons with late AMD at
entry of the study. Genotype frequencies were in Hardy-Weinberg
Equilibrium in both studies. The population frequency of ERCC6
G allele was 0.43. Baseline characteristics stratified for the ERCC6
c.-6530C.G genotype are presented in Table S1.
The risk of AMD for the ERCC6 c.6530C.G allele is
summarized in Table S2. In the Rotterdam Study, we found a
significant association between ERCC6 and late AMD in the
incident analyses. Although not statistically significant, a similar
trend was seen in the prevalent analyses. In contrast, analysis of
the AMRO-NL study showed no significantly increased disease
OR for persons carrying potential ERCC6 risk alleles. To
determine the risk for the general Dutch population, we combined
data from the Rotterdam Study and the AMRO-NL study
population. This yielded a borderline significant increased risk of
late AMD for persons homozygous for rs3793784 (OR 1.39,
95%CI 1.02–1.89). Analyzing subtypes of late AMD separately
(dry, wet or mixed) did not yield statistical significant results:
Table S2. We also analyzed the interaction of ERCC6 c.-
6530C.G with three known prominent AMD risk factors in the
largest combined population study available to us (The Dutch
Rotterdam and AMRO-NL studies). As assessed by calculation of
the synergy index (SI) no significant interaction between the
ERCC6 variant and smoking was found (SI 3.33, 95%CI 0.39–
28.66). Neither did we find a significant SI for the interaction with
CFH Y402H (SI 1.56, 95%CI 0.77–3.15) and LOC387715 A69S
(SI 3.08, 95%CI 0.83–11.50). These results implied that these risk
factors did not modify the relation of ERCC6 with AMD.
Finally, rs3793784 was also screened in two non-European
study populations (Columbia and AREDS). The results from the
genotype analysis of these populations are shown in Table 1.
Again, all the genotype frequencies followed HWE (data not
shown). However, in both populations, no significant associations
between the SNP and AMD were found. Table 2 shows that
combining all data from the four studies did not result in
statistically significant association.
AMD association analysis of nine other ERCC6 variants
We next selected nine other ERCC6 SNPs that span and tag the
entire ERCC6 gene. The LD plot and the distinct haplotype blocks
for the nine selected SNPs, as generated by Haploview [31], are
The ERCC6 Gene and AMD
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haplotype blocks of the ERCC6 gene. Corresponding LD scores
(D’ and R
2) for each selected marker of the ERCC6 gene with a
MAF.10% are also given (Figure 1b). The potential association
of the SNPs with early and late AMD was analyzed in the AMRO-
NL cohort. Genotype frequencies for all SNPs followed HWE
(data not shown). None of the selected SNPs, including one in full
LD with rs3793784 (rs2229760), showed a significant association
with early or late AMD (Table S3).
ERCC6 mRNA expression in the human RPE
SNP rs3793784 reportedly influences ERCC6 gene expression,
with the risk allele (G) showing higher expression [19]. We first
genotyped this ERCC6 SNP in DNA derived from the retina of 23
well characterized healthy old and early AMD affected donor eyes.
We next determined ERCC6 mRNA expression in laser dissected
RPE cells from the same eyes, since this cell type occupies a central
position in AMD pathology. Late AMD was not considered for
RPE expression studies because of the lack of suitable cell material.
There were no significant differences in age distribution between
each genotype group. The results are presented in Figures 2a
and 2b. Clearly, in the RPE, the risk allele (G) of rs3793784 did
not lead to higher ERCC6 expression levels. A two way ANOVA
was used to statistically test the effect of genotype and AMD status
on ERCC6 expression. The ANOVA did not detect an
independent significant effect for rs3793784 genotype on ERCC6
expression (Figure 2a; P=0.293). In addition, the combined
effect of genotype and AMD status on ERCC6 expression was not
significant either (Pinteraction=0.531). However, the ANOVA did
demonstrate a significant effect of AMD status on ERCC6
expression, independent of the rs3793784 genotype (Figure 2b,
P=0.018). Interestingly, the expression of ERCC6 in healthy RPE
was nearly twice as high as in early AMD affected RPE
(Figure 2b). The ‘‘raw’’ data of the three housekeeping genes
and the ERCC6 gene is presented in Table S4.
Discussion
We genotyped the ERCC6 promoter SNP rs3793784, which was
previously associated with AMD, in the prospective, population
Table 1. Risk of Age-Related Macular Degeneration for ERCC6 c.-6530C.G Genotypes in Two Non-European Study Populations.
No AMD
(controls)
All AMD
cases Early AMD NMD GA Mixed AMD Late AMD
AREDS
rs3793784 N=217 N=921 N=253 N=324 N=166 N=178 N=668
No. (%) No. (%) OR (95% CI)No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI)
Genotype
Noncarrier
(AA)
82 (37.8) 310 (33.6) 1 83 (32.8) 1 108 (33.3) 1 56
(33.7)
16 3
(35.4)
1 227 (34.0) 1
Heterozygous
(Aa)
98 (45.2) 462 (50.2) 1.25
(0.8921.73)
136 (53.8) 1.37
(0.9222.05)
161 (49.7) 1.25
(0.8521.83)
80
(48.2)
1.19
(0.7621.88)
85
(47.8)
1.13
(0.7321.75)
326 (48.8) 1.20
(0.8621.69)
Homozygous
(aa)
37 (17.1) 149 (16.2) 1.07
(0.6921.65)
34 (13.4) 0.91
(0.5221.58)
55 (17.0) 1.13
(0.6821.87)
30
(18.1)
1.19
(0.6622.14)
30
(16.9)
1.05
(0.5921.89)
115 (17.2) 1.13
(0.7221.76)
MAF(%) 0.40 0.41 0.40 0.42 0.42 0.41 0.42
Columbia
rs3793784 N=359 N=365 N=273 N=92 N=365
No. (%) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI)
Genotype
Noncarrier
(AA)
135 (37.6) 149 (40.8) 1 115 (42.1) 1 34
(37.0)
1 149 (40.8) 1
Heterozygous
(Aa)
172 (47.9) 169 (46.3) 0.89
(0.6521.22)
124 (45.4) 0.85
(0.6021.19)
45
(48.9)
1.04
(0.6321.71)
169 (46.3) 0.89
(0.6521.22)
Homozygous
(aa)
52 (14.5) 47 (12.9) 0.82
(0.5221.29)
34 (12.5) 0.77
(0.4721.36)
13
(14.1)
0.99
(0.4922.03)
47 (12.9) 0.82
(0.5221.29)
MAF(%) 0.38 0.36 0.35 0.39 0.36
AMD = age-related macular degeneration; MAF = minor allele frequency. ‘‘A’’ indicates common allele, ‘‘a’’ minor allele. Percentages not always 100% because of
rounding. ORs are estimated with logistic regression analysis (with the control group as reference group and respectively early and late AMD as outcome variable).
doi:10.1371/journal.pone.0013786.t001
Table 2. Risk of Age-Related Macular Degeneration for ERCC6
c.-6530C.G Genotypes in all Study Populations Combined
(Rotterdam, Amsterdam, Columbia University and AREDS).
No AMD (controls) AMD cases
rs3793784 N=3143 N=2679
No. (%) No. (%) OR (95% CI)
Genotype
Noncarrier (AA) 1057 (33.6) 898 (33.5) 1
Heterozygous (Aa) 1524 (48.5) 1316 (49.1) 0.89 (0.6521.22)
Homozygous (aa) 562 (17.9) 465 (17.4) 0.82 (0.5221.29)
MAF (%) 0.42 0.42
AMD = age-related macular degeneration; MAF = minor allele frequency. ‘‘A’’
indicates common allele, ‘‘a’’ minor allele. Percentages not always 100%
because of rounding. ORs are estimated with logistic regression analysis (with
the control group as reference group and respectively early and late AMD as
outcome variable).
doi:10.1371/journal.pone.0013786.t002
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case control study. In addition, we screened two other large, non-
European, study populations (Columbia University, NY and
AREDS) of European-American descent. In total, this study
consisted of 2682 AMDcasesand3152 ethnically matched controls.
Non-replication of the rs3793784 SNP association with
AMD
Contrary to the findings of the initial association study by Tuo
et al. (2006) [19], we failed to show a (consistent) statistically
significant association between rs3793784 and AMD in all study
populations.
We only detected a significant risk in the incident analysis of the
Rotterdam Study, but not in the prevalent analysis. This prompted
us to specifically analyze whether selective mortality may be
involved: persons with two copies of ERCC6 rs3793784 have a
higher risk of AMD, and if these persons also die earlier, it could
explain the discrepancy between prevalent and incident analyses.
However, in the Rotterdam Study, the ERCC6 variant was not
associated with increased mortality (not shown); in addition, there
Figure 1. Linkage disequilibrium (LD) display in Haploview of SNPs encompassing the ERCC6 gene. SNP selection was based on criteria
like functional relevance, minor allele frequency (MAF).10%, coverage of the main linkage disequilibrium (LD) blocks and tagging of the most
common haplotypes. Tag SNPs were selected by use of Tagger, an option of Haploview [1] (all SNPs were captured with a LD tagging criteria of
r
2.0.8). Figure 1 displays the 5 distinct haplotype blocks and all SNPs that were tested in the AMRO-NL study population (A). LD scores (D’ and R
2)
between markers genotyped. Note D’ above the diagonal and R
2 scores below the diagonal (B).
doi:10.1371/journal.pone.0013786.g001
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Thus, the small difference between the incident and prevalent risks
in the population based cohort probably occurred by chance due
to relatively small patient sample sizes. In the AMRO-NL case-
control study, association between the rs3793784 SNP and AMD
was not found. The combined data of the two Dutch populations
(the Rotterdam Study and AMRO-NL study) still showed a
marginally increased risk of homozygous ERCC6 carriers for late
AMD. Since this effect was largely caused by one sub-population
only (incident cases and controls from the Rotterdam study), we
chose to include two additional study populations. Replication of
the association in two non-European study populations clearly
failed: In both the Columbia University and AREDS data, no
association was present between rs3793784 and AMD.
Our negative association findings in the AREDS population are
of particular interest: Tuo et al. [19] previously genotyped the
ERCC6 SNP rs3793784 essentially in the same AREDS cohort and
did find a statistically significant association. How can this
Figure 2. ERCC6 expression levels in relation to genotype and disease status. Mean ERCC6 expression level in human donor eyes in relation
to rs3793784 genotype (C/C, N=8; C/G, N=11and G/G, N=4). (A). Mean ERCC6 expression level in human donor eyes in relation to ‘‘status’’= (old)
healthy or early AMD (N =14 donor eyes with early AMD and 9 old healthy donor eyes) (B). Quantitative RT-PCR analysis, normalized to the geometric
mean of three housekeeping genes (RPLP0, PPIA, and EEF1a1) [46,47]. Two way ANOVA was used to test the independent effect of status and
genotype on the mean expression, as well as the interaction between these variables. Abbreviations: AMD= age-related macular degeneration.
doi:10.1371/journal.pone.0013786.g002
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difference in the number of AREDS participants screened: Tuo et
al. [19] genotyped 460 cases and 269 controls, whereas in our
AREDS screen, 929 cases and 217 controls were genotyped.
Further analysis showed that the MAF of rs3793784 in the cases
are comparable in both studies (0.42/0.41). However, the MAF of
rs3793784 in the controls of both studies is remarkably different
(AREDS Tuo: 0.35 and our AREDS study: 0.40). The Rotterdam
Study, AMRO-NL study and the Columbia study yield MAFs of,
respectively, 0.43, 0.42 and 0.38 in controls. Thus, we conclude
that the findings of Tuo and coworkers (MAF 0.35 in the controls),
and the underlying association with AMD, are most likely due to
chance. In addition, in contrast with the data of Tuo et al. [19], we
also did not find evidence for effect modification or interaction
between CFH Y402H or any of the other two major AMD risk
factors: smoking or the LOC387715 A69S SNP. Overall, the
possible weak association in a single Dutch sub-population and the
negative association in three large replication cohorts, imply that
the ERCC6 C-6530.G polymorphism has a minor role, if any, in
the pathogenesis of AMD. This conclusion is supported by a
recent study by Chen and coworkers, who conducted a genome-
wide association scan for AMD in 2157 cases and 1150 controls.
Amongst other, they evaluated evidence for involvement of
previously associated SNPs and found no association between
the ERCC6 SNP rs3793784 and AMD [32].
Finally, it is of course possible that another genetic variant or a
variant in linkage disequilibrium (LD) with ERCC6 -6530C.G,i sa
contributor to the potential AMD risk observed. In order to
further elucidate the putative role of this gene in AMD we tested
nine other common ERCC6 variants in the AMRO-NL study.
One of these SNPs was in perfect LD with the previously
associated SNP, rs2229760. None of the selected SNPs showed a
significant association with early or late AMD. These results
strengthen the conclusion described above and suggest that
common SNPs in the ERCC6 gene confer no or little risk for
AMD.
ERCC6 expression in the human RPE is related to AMD
status, not to rs3793784 genotype
Tuo et al. (2006) found that rs3793784, located in the
untranslated 59 flanking region of the gene, influenced ERCC6
expression level: the risk allele (G) resulted in 2–3 times higher
ERCC6 expression than the C variant [19]. This is an intriguing
finding since it suggests that higher expression of this DNA repair
gene makes the retina more susceptible to AMD. We decided to
examine ERCC6 mRNA expression in the human RPE, which
occupies a central position in AMD pathology. In this cell type, we
could not reproduce the paradoxical finding of Tuo and co-
workers [19]. Instead, we found that ERCC6 RPE expression levels
were significantly reduced in early AMD affected eyes, independent of
rs3793784 genotype.
The significantly reduced expression of ERCC6 in the RPE of
early AMD affected eyes, suggests that ERCC6 is involved in
AMD. It is plausible that this involvement relates to oxidative
stress and aging. Functional studies have implicated oxidative
stress in the RPE in the aetiology of AMD [33,34], while
epidemiological studies unanimously consider aging as the main
risk for AMD [35]. At the same time, ERCC6 plays a role in repair
of (oxidative) DNA damage. Loss of function mutations in ERCC6
cause the autosomal recessive disorder Cockayne syndrome, which
includes many severe physical and neurologic features, with
premature aging and retinopathy as hallmarks of the disease.
These observations led to the hypothesis that (oxidative) DNA
damage and insufficient DNA repair contribute to aging pathol-
ogy, including AMD [36]. This hypothesis was supported by a
recent study, which compared DNA repair capacity in leukocytes of
AMD patients and controls: Wozniak and co-workers found that
AMD patients had higher levels of endogenous oxidative DNA
damage and a lower repair capacity of DNA lesions [37].
We found that early AMD affected eyes had an almost 50%
reduced expression of ERCC6 in the RPE. In CS patients both
ERCC6 alleles carry loss of function mutations [20,21]. To our
knowledge, 50% reduction in transcription levels in CS carriers
has not been reported to lead to pathology. Yet, it should be noted,
that clinical data on CS carriers are scarce and, most likely, they
have not been screened for retinal (AMD) pathology. Interestingly,
repair of the 8-oxoguanine DNA lesion was investigated in a CS
family: It was found that cells from the heterozygous parents had
intermediate levels of repair of this oxidative DNA lesion
compared to their CS affected and unaffected siblings [38]. It is
important in this respect that most retinal cells, including the RPE
are post-mitotic cells and that they are exposed to extremely high
levels of oxidative stress over the prolonged period of (a life-) time.
It is therefore conceivable that in this particular organ, the repair
of oxidative DNA damage may be even more demanding than in
other tissues. Small but prolonged shortcomings in DNA repair
may, eventually, at advanced age become manifest in more
damage and cell death than in other tissues. In this way, reduced
levels of ERCC6 in the RPE may well contribute to the
development of AMD.
The cause of the reduced ERCC6 transcription in RPE of early
AMD affected eyes is not clear. However, given its implication in
the multifactorial disorder AMD, and our inability to associate
common ERCC6 SNPs with AMD, we hypothesize that the
genetic involvement of ERCC6 in AMD, if any, may reside in
(combination of) rare SNPs. Alternatively, the reduction in ERCC6
transcription levels in relation to AMD may also be due to other
genetic factors or to environmental insults, such as prolonged
smoking.
Conclusion
In summary, our study did not confirm a consistent relation
between common genetic variation in ERCC6 and AMD. We did
not find a significant interaction between ERCC6 SNP rs3793784
and either smoking, CFH or LOC387715. Using RPE from human
donor eyes, we also could not confirm rs3793784 genotype
dependent expression of ERCC6.
We did find significantly lower expression levels of ERCC6 in
human RPE affected by early AMD, regardless of the rs3793784
genotype. The latter finding suggests that ERCC6 may be
functionally implicated in the aetiology of AMD. Combining our
data with those of the literature, we hypothesize that the AMD-
related reduced transcriptional activity of ERCC6 expression may
be caused by diverse, small and heterogeneous genetic and/or
environmental determinants.
Materials and Methods
Ethics Statement
All studies were approved by the Ethics Committees of the
Academic Medical Center Amsterdam, the Erasmus Medical
Center Rotterdam, the Institutional Review Board of Columbia
University and the Age-Related Eye Disease Study (AREDS)
Access Committee. All studies followed the tenets of the
Declaration of Helsinki. All participants provided signed informed
consent for participation in the study, retrieval of medical records,
and use of blood and DNA for AMD research.
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Altogether, we utilized one prospective, population-based study
and three case-control studies consisting of 2682 AMD cases and
3152 ethnically- and age-matched control subjects.
Study populations
Genetic association of the ERCC6 SNP rs3793784 was analyzed
in the Rotterdam Study and, in parallel, in the AMRO-NL case-
control study population. Next, replication was carried out in two
non-European study populations (Columbia University and
AREDS). Finally, nine ERCC6 (tag) SNPs were genotyped in the
AMRO-NL study population.
In The Rotterdam Study all inhabitants of 55 years or older living in
a suburb of Rotterdam, the Netherlands, were invited to
participate [39,40]. The initial cohort consisted of 10,275 eligible
individuals, of whom 7,983 (78%) participated (98% Caucasian).
The ophthalmologic part of the study consisted of 9,774 eligible
individuals, of whom 7,598 (78%) participated. Baseline exami-
nations took place from 1990 to 1993; three follow-up examina-
tions were performed in 1993–1994, 1997–1999, and 2000–2005.
Incident cases were defined as the absence of AMD in both eyes at
baseline and its first appearance in at least 1 eye at follow-up.
The AMRO-NL study population consisted of 375 unrelated AMD
patients and 199 controls. All subjects were Caucasian and
recruited from the Netherlands Institute of Neuroscience Am-
sterdam and Erasmus University Medical Centre Rotterdam
(Amsterdam-Rotterdam-NL (AMRO-NL)), through newsletters,
via patient organizations, and nursing home visits. Controls were
aged 65 years and older, and were unaffected spouses or non-
related acquaintances of cases, or individuals who attended the
ophthalmology department for reasons other than retinal
pathology.
Cases and controls from the Columbia University study population,
consisted of 368 unrelated individuals with AMD and 368
unrelated controls of European American descent, recruited at
Columbia University (New York, NY) as previously described [6].
The AREDS study population was initially conceived as a long-term
multicenter, prospective study of the clinical course of AMD and
age-related cataract. Briefly, patients over the age of 55 years who
self-reported to participating eye clinics between 1992 and 1996
were considered for AREDS, and eligibility was based on AMD
symptoms and retinal photographs. A total of 1,699 patients were
selected and enrolled in the clinical trial, all were put into one of
five AMD severity categories, and then randomized into
intervention and non-intervention groups. In this sample set,
there were 929 AMD cases and 217 patients, free of AMD, acted
as controls. The full details and results of the original AREDS
study are reported elsewhere [41,42].
Diagnosis of AMD
Study subjects from the Rotterdam, AMRO-NL and Columbia
University study populations underwent ophthalmic examination
and fundus photography covering a 35u field centered on the
macula after pupil dilatation at each visit (Topcon TRV-50VT
fundus camera, Topcon Optical Co, Tokyo, Japan). Signs of AMD
in those study populations were graded according to (a
modification of) the international classification and grading system
for AMD [43]. Cases and controls from the AREDS study were
classified as having or not having disease on the basis of the
AREDS classification system [44]. Although AREDS uses slightly
different criteria for classification of early AMD and GA, the
grading criteria were very similar for the four studies. Controls
showed no, or less than five small hard drusen, and no other
macular pathology. Early AMD cases had either soft distinct
drusen with pigmentary irregularities or soft indistinct drusen with
or without pigmentary irregularities. Late AMD cases presented
with dry AMD, wet AMD, or a combination of both (mixed
AMD).
Genotyping
Standard DNA techniques were applied as described elsewhere
[45]. Genotyping of the polymorphisms rs3793784 (ERCC6 c.-
6530C.G), rs1061170 (CFH Y402H) and rs10490924 (LOC387715
A69S) were done with the Taqman assay (Applied Biosystems,
Foster City, CA). Genotyping of the nine ERCC6 (tag) SNPs was
performed using an Illumina GoldenGate assay on a BeadStation
500 GX (Illumina Inc., San Diego,CA, US).
ERCC6 Tag SNP selection for Illumina GoldenGate assay
Nine SNPs were selected to span and tag the entire ERCC6
gene. SNP data were used from the Centre d’E ´tude du
Polymorphisme Humain (CEPH) population (Utah residents with
ancestry from northern and western Europe) by use of the
International HapMAP Project. Available at: http://www.
hapmap.org/, NCBI build 36, dbSNP b126; Accessed January
7, 2009. SNP selection was based on criteria like functional
relevance, minor allele frequency (MAF).10%, coverage of the
main linkage disequilibrium (LD) blocks and tagging of the most
common haplotypes. Tag SNPs were selected by use of Tagger, an
option of Haploview [31] (all SNPs were captured with a LD
tagging criteria of r
2.0.8).
Human donor eyes and ERCC6 expression
Postmortem eyes. Studies on human eye tissue were carried
out in accordance with the Declaration of Helsinki on the use of
human material for research. Donor eyes were obtained from the
Corneabank Amsterdam. The method of selection of eyes for this
study was essentially described elsewhere [18]. In summary,
medical history of the donors revealed no pre-existing disorders,
prolonged medication, or other prolonged agonal states that could
possibly influence RPE gene expression or mRNA quality.
Histological analysis was performed on all donor eyes, e.g. by
staining with the periodic acid Schiff staining protocol (of sections
(10 mm long) of the macula to identify and quantify drusen.
Donor eyes were categorized into (1) ‘‘(old) healthy’’, if the donor
was older than 70 and histology revealed no drusen (on average 0–
1 per 10 macular cryo-sections), and (2) ‘‘early AMD’’, if the donor
was older than 70 and histology showed 30 or more drusen per 10
macular cryo-sections with a still intact RPE.
Rs3793784 genotyping. Tuo et al. (2005) showed that
ERCC6 rs3793784, located in the untranslated 59 flanking region
of the gene, influenced ERCC6 expression level: the G allele
resulted in 2–3 times higher ERCC6 expression than the C variant
[19]. Therefore, genotyping of this SNP was performed on all
above described donor eyes. Genomic DNA was prepared from
frozen bulbi by standard extraction protocol using phenol. PCR
and direct sequence analysis was carried out as previously
described [46] with the use of the ABI-310 automated sequencer
(Applied Biosystems).
ERCC6 mRNA expression in the RPE of human donor
eyes. We measured ERCC6 mRNA expression in the RPE cells
with real-time qPCR, in triplicate [47]. In summary, human donor
eyes were snap-frozen in isopentane (Sigma-Aldrich, England) and
stored at 280uC. Cryosections of 20 mm from the macula were cut
and RPE cells were dissected using a PALM laser dissection
microscope (P.A.L.M. Micro Laser Technologies AG). Total RNA
was isolated with RNeasy mini (Qiagen) and amplified with the
MessageAmp aRNA kit (Ambion). Template cDNA for the real-
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with Superscript III (Invitrogen). Real-time PCR reactions were
carried out in a 20 ml volume using qPCR Core Kit Sybr Green I
(Eurogentec) and the following primer set: 59-59AAATCT-
GTGCACTTTCCATAGAACTTC-39 and 59- Reverse: TATT-
CTGGCTTGAGTTTCCAAATTC-39. The levels of amplified
product were detected by real-time monitoring of SYBR Green I
dye fluorescence in the ABI Prism 7300 (Applied Biosystems).
Expression levels of ERCC6 were normalized using the geo-mean
of the expression of internal control genes RPLP0, PPIA, and
EEF1a1 [47,48]. Over ten different combinations of primersets
were tested to obtain, in our hands and under our experimental
conditions, the optimum reference gene set for genes expressed in
the RPE (and/or photoreceptors). Two way ANOVA was used to
determine the independent effect of (AMD) status and rs3793784
genotype on the mean expression as well as the interaction
between these two variables. Significance was accepted at a P
value of ,0.05.
Statistical analysis
Characteristics of the Dutch participants were compared among
those affected and non-affected with analysis of covariance for
continuous variables, and with logistic regression analysis for
discrete variables adjusting for age and sex.
Hardy-Weinberg Equilibrium (HWE) of the ERCC6, CFH and
LOC387715 genotype distributions were tested using a Chi
2 test.
In the Rotterdam Study, odds ratio’s for prevalent AMD were
estimated with logistic regression analyses, and relative risks for
incident AMD were estimated with Cox proportional hazards
analyses. Logistic regression was used in the AMRO-NL and the
replication studies of Columbia University and AREDS to
calculate odds ratios (ORs) and 95% confidence intervals (CI) in
SPSS for windows (release 16.0; SPSS, Inc) for risk of AMD with
the major alleles as reference. For the Rotterdam Study and the
AMRO-NL study population, ORs were adjusted for age and sex.
Interaction with ERCC6 c.-6530C.G on AMD was determined
for smoking, CFH Y402H, and LOC387715 A69S contrasting late
AMD with no AMD. Analyses were initially performed on
separate data sets of the Rotterdam Study (prevalent AMD,
incident AMD), the AMRO-NL case-control study (in parallel),
and subsequently conducted on combined data from the Nether-
lands (of population-based and case-control groups) and data of all
population studies combined. Statistical significance for biological
interaction was determined by calculating the synergy index (SI),
which measures deviation from additivity of two risk factors
[49,50]. Two way ANOVA analysis was performed in SPSS for
windows (release 16.0; SPSS, Inc).
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Table S1 Baseline characteristics of the study populations.
Found at: doi:10.1371/journal.pone.0013786.s001 (0.05 MB
DOC)
Table S2 Risk of age-related macular degeneration for ERCC6
c.-6530C.G genotypes. Abbreviations: AMD, age-related macu-
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HRs are estimates of the relative risk of AMD, and represent the
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by the risk of disease (AMD vs stage 0) in the nonrisk group
(noncarriers).a adjusted for sex, age.
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Table S3 Odds Ratios (OR) and 95% Confidence Intervals (CI)
of early and late age-related macular degeneration cases versus
unrelated controls of the Amsterdam study population for single
nucleotide polymorphisms in the ERCC6 gene. AMD = age-
related macular degeneration; MAF = minor allele frequency.
‘‘A’’ indicates common allele, ‘‘a’’ minor allele. Percentages not
always 100% because of rounding. ORs are estimated with logistic
regression analysis (with the control group as reference group and
respectively early and late AMD as outcome variable). Adjusted
for age and sex.
Found at: doi:10.1371/journal.pone.0013786.s003 (0.10 MB
DOC)
Table S4 RT-PCR analysis of ERCC6 gene expression in RPE
from eye donors with early AMD or non-affected age-matched
donors. Both raw expression values for the three selected RPE
housekeeping genes (RPLP0, PPIA, and EEF1a1) and ERCC6, as
well as the resulting normalized expression values for ERCC6 are
presented. AMD= age- related macular degeneration. Normal-
ization= normalized to the geometric mean of three housekeeping
genes (RPLP0, PPIA, and EEF1a1) [46,47]. For statistical details
see material and methods.
Found at: doi:10.1371/journal.pone.0013786.s004 (0.06 MB
DOC)
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